Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD99 CAR-T for recurrent or refractory CD99-positive lymphoproliferative diseases
ChiCTR2000033989Phase 2Recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Jul 2020
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CD99 CAR-T in lymphoproliferative disorder (LPD), T-cell lymphoproliferative disorder (TLPD), t-cell acute lymphoblastic leukemia (T-ALL) and 8 more, sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoints: Objective response rate, Complete remission rate and 2 more. Started Jul 2020; status: recruiting.
02
Drugs
CD99 CAR-T
03
Conditions
lymphoproliferative disorder (LPD)T-cell lymphoproliferative disorder (TLPD)t-cell acute lymphoblastic leukemia (T-ALL)Ewing sarcomaacute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2000033989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033989.